N@N

AbbVie Named to Samp;;P 500 Dividend Aristocrat Index

^{Published on 2013-01-21 07:15:23 - Market Wire}
 

AbbVie Named to S&P 500 Dividend Aristocrat Index -- NORTH CHICAGO, Ill., Jan. 21, 2013 /PRNewswire/ --

NORTH CHICAGO, Ill., Jan. 21, 2013 /PRNewswire/ -- AbbVie (NYSE: [ ABBV ]), a global biopharmaceutical company, has been named to the S&P 500 Dividend Aristocrat Index for 2013.

The Dividend Aristocrat Index measures the performance of dividend-paying companies within the S&P 500 Index that have followed a policy of increasing dividends each year for at least 25 consecutive years.  In 2013, only 54 companies, approximately 11 percent of companies named to the S&P 500 Index, were included in this year's update. 

"AbbVie is honored to be included among the premier dividend-paying companies which are represented by this Index," said Bill Chase , executive vice president and chief financial officer, AbbVie. "AbbVie is committed to delivering attractive shareholder returns through a strong and sustainable dividend which we intend to grow in the future."

AbbVie was included as a result of the Index's change in its treatment of spin-off companies.  AbbVie was also named to the S&P High Yield Dividend Aristocrats Index, which measures the performance of companies within the S&P Composite 1500 that have followed a policy of increasing dividends each year for at least 20 consecutive years.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit [ www.abbvie.com ]. Follow [ @abbvie ] on Twitter or view careers on our [ Facebook ] or [ LinkedIn ] page.

SOURCE AbbVie